

Serial No. 10/042,818

Supplemental Amendment to Amendment of 10/14/03

REMARKS

THE TELECONFERENCE

In a teleconference held on December 30, 2003, the Examiner indicated to Applicant's attorney that the application would be deemed allowable if particular amendments to the claims were made. Applicant's attorney thanks the Examiner for the many courtesies extended in the course of the interview and for the suggestions regarding the amendment of the claims. By the present amendment, the claims have been rewritten in conformity with the Examiner's requests, and it is respectfully submitted that this application is in condition for allowance.

STATUS

Claims 1, 3-7, 9-13, 15-20, and 22-26 were at issue in the course of the interview. By the present amendment, claims 9, 11-18, and 23-26 have been cancelled. New claims 27-29 have been added. Accordingly, it is now claims 1, 3-7, 10, 19, 20, 22, and 27-29 which are at issue.

THE AMENDED CLAIMS

Applicant will briefly summarize the substance of the amendments which have been made pursuant to the Examiner's suggestions. Claim 1 has been recast in partially closed "consisting essentially of" form.

Claim 9 which was dependent on original claim 1 has been cancelled and rewritten in independent form as claim 27. This claim is in partially closed form and tracks amended claim 1 and further recites that the composition includes a topical corticosteroid. Claim 11, which was dependent on claim 1 has been cancelled and replaced by new claim 28. New claim 28 is in

Serial No. 10/042,818

Supplemental Amendment to Amendment of 10/14/03

partially closed format and tracks amended claim 1 and adds the further limitation that the composition includes an additional therapeutic material selected from a recited Markush group.

Claim 19 is a method claim directed to the use of a composition of the type recited in claim

1. Claim 19 has now been amended to recite the composition in partially closed form.

Claim 23 which was originally dependent on claim 19 has been cancelled and replaced by new independent claim 29 which basically tracks amended claim 19 and further adds a Markush group of ancillary therapeutic materials. Applicant notes for the record that the originally recited group in claim 23 has been expanded in new claim 29 to further include a topical corticosteroid. Use of this material in the therapeutic method is disclosed extensively throughout the specification, and is also the subject matter of new claim 27. In this regard, claim 29 is a combination of composition claims 27 and 28 cast into method format.

CONCLUSION

Applicant again thanks the Examiner for the courtesies extended in the course of the interview. The present amendment revises the claims per the agreement reached in the course of the interview, and places the application in condition for allowance.


GIFFORD, KRASS, GROH, SPRINKLE, ANDERSON & CITKOWSKI, P.C. 280 N. OLD WOODWARD AVENUE, STE. 400, BIRMINGHAM, MICHIGAN 48009-5394 (248) 647-6000

Serial No. 10/042,818

Supplemental Amendment to Amendment of 10/14/03

Any questions, comments, or suggestions the Examiner may have which will place the application in still better condition for allowance, should be directed to the undersigned attorney.

Respectfully submitted,


Ronald W. Citkowski, Reg. No. 31,005
Gifford, Krass, Groh, Sprinkle,
Anderson & Citkowski, P.C.
280 N. Old Woodward Ave., Suite 400
Birmingham, MI 48009-5394
(248) 647-6000
Attorney for Applicant

RWC/aka

am-W:\Word Processing\rwc\fil10502-suppamd.doc

GIFFORD, KRASS, GROH, SPRINKLE, ANDERSON & CITKOWSKI, P.C. 280 N. OLD WOODWARD AVENUE, STE. 400, BIRMINGHAM, MICHIGAN 48009-5394 (248) 647-6000

Serial No. 10/042,818

Supplemental Amendment to Amendment of 10/14/03

CERTIFICATE OF TRANSMISSION VIA FACSIMILE

I hereby certify that this correspondence is being sent to the United States Patent Office, Examiner Gollamudi S. Kishore via facsimile (703-746-5112) on December 30, 2003.


Janice Burkhardt